Sulbactam‐durlobactam: A novel β‐lactam‐β‐lactamase inhibitor combination targeting carbapenem‐resistant <i>Acinetobacter baumannii</i> infections
Amer El Ghali(University of New Mexico), Michael J. Rybak(Eugene Applebaum College of Pharmacy and Health Sciences)
Cited by 50
Related Papers
Clinical Practice Guidelines by the Infectious Diseases Society of America for the Treatment of Methicillin-Resistant Staphylococcus aureus Infections in Adults and Children
|Clinical Infectious Diseases|2011|4.2k
Therapeutic monitoring of vancomycin in adult patients: A consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists
|American Journal of Health-System Pharmacy|2008|1.8k
Clinical Practice Guidelines by the Infectious Diseases Society of America for the Treatment of Methicillin-Resistant Staphylococcus aureus Infections in Adults and Children: Executive Summary
|Clinical Infectious Diseases|2011|1.6k
Therapeutic Monitoring of Vancomycin in Adults
|Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy|2009|399
Meropenem and Vaborbactam: Stepping up the Battle against Carbapenem‐resistant Enterobacteriaceae
|Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy|2018|85